What changed in this filing

/stocks — the workspaceLOADING

Item 2. Unregistered Sales of Equity Securities

2021-05-07 compared with 2020-11-05 · 42 added, 23 removed, 14 unchanged (82% of the section changed)

1 unchanged sentence

Issuer Purchases of Equity Securities

On May 2, 2019, we announced that our Board of Directors approved a $50.0 million share repurchase program with $30.0 million to be utilized for an accelerated share repurchase program and $20.0 million reserved for open market purchases.

We did not repurchase any shares during the three-month period ended September 30, 2020, and a total of $20.0 million remained available for open market repurchases as of September 30, 2020.

Offer Letter dated as of July 29, 2020 between Anika Therapeutics, Inc.

and Michael 

Rule 13a-14(a)/15d-14(a) Certifications

Under our equity compensation plans, and subject to the specific approval of the Compensation Committee of our Board of Directors, grantees have the option of electing to satisfy tax withholding obligations at the time of vesting or exercise by allowing us to withhold shares of stock otherwise issuable to the grantee.

During the three-month period ended March 31, 2021, we withheld 8,972 shares to satisfy grantee tax withholding obligations on restricted stock unit vesting events.

Following is a summary of stock repurchases for the three-month period ended March 31, 2021 (in thousands, except share data):

Total Number of

Shares Purchased as Part of Publicly Announced Plans or Programs (2)

Price per Share

Maximum Number (or Approximate Dollar Value) of Shares that May Yet be Purchased Under the Plans or Programs(1)

January 1 to 31, 2021

February 1 to 28, 2021

March 1 to 31, 2021

Through March 31, 2021, we had made no open market repurchases.

On May 7, 2019, we entered into a previously-announced accelerated share repurchase agreement, or the ASR Agreement, to repurchase an aggregate of $30.0 million of common stock.

During the second quarter of 2019, 451,694 shares were delivered to us, constituting the initial delivery of shares and representing 60% of the then estimated total number of shares expected to be repurchased under the ASR Agreement.

On January 14, 2020, pursuant to the terms of the ASR Agreement, Morgan Stanley accelerated the final settlement date from February 2020, and the final number of shares and the average purchase price was determined.

Based on the volume-weighted average price from the effective date of the ASR Agreement through January 14, 2020, less the applicable contractual discount, Morgan Stanley delivered 139,057 additional shares to us on January 17, 2020.

In total, 590,751 shares were repurchased under the ASR Agreement at an average repurchase price of approximately $50.78.

All shares were repurchased in accordance with the publicly announced program.

8,972 shares were withheld by us to satisfy grantee tax withholding obligations on restricted stock unit vesting events in February 2021.

Exhibit No.  

Form of Notice of Grant of Incentive Stock Option, including Terms and Conditions of Stock Option, granted under Anika Therapeutics, Inc.

2017 Omnibus Incentive Plan

Form of Notice of Grant of Nonqualified Stock Option, including Terms and Conditions of Stock Option, granted under Anika Therapeutics, Inc.

2017 Omnibus Incentive Plan

Form of Notice of Grant of Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under Anika Therapeutics, Inc.

2017 Omnibus Incentive Plan

Form of Notice of Grant of Deferred Stock Awards Units, including Terms and Conditions of Deferred Stock Units, granted under Anika Therapeutics, Inc.

2017 Omnibus Incentive Plan

Rule 13a-14(a)/15d-14(a) Certifications

Certification of Dr.

Blanchard, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Michael Levitz, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Section 1350 Certifications

Blanchard, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Michael Levitz, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Section 1350 Certifications

Certification of Dr.

Blanchard, and Michael Levitz, pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.

The following materials from Anika Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 as filed with the Securities and Exchange Commission on November 4, 2020, formatted in Inline XBRL (eXtensible Business Reporting Language), as follows:

Consolidated Balance Sheets as of September 30, 2020 (unaudited) and December 31, 2019 (unaudited)

ii.          

Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2020 and September 30, 2019 (unaudited)

iii.        

Consolidated Statements of Stockholders’

Equity for the nine months ended September 30, 2020 and September 30, 2019 (unaudited)

iv.        

Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and September 30, 2019 (unaudited)

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

The following materials from Anika Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 as filed with the SEC on May 6, 2021, formatted in Inline XBRL (eXtensible Business Reporting Language), as follows:

Consolidated Balance Sheets as of March 31, 2021 (unaudited) and December 31, 2020 (unaudited)

Consolidated Statements of Operations and Comprehensive Income for the Three Months Ended March 31, 2021 and March 31, 2020 (unaudited)

Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2021 and March 31, 2020 (unaudited)

Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2021 and March 31, 2020 (unaudited)

Notes to Consolidated Financial Statements (unaudited)

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) 

Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(2).

The omitted information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

Filed herewith.

2 unchanged sentences

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ANIKA THERAPEUTICS, INC.

November 4, 2020

ANIKA THERAPEUTICS, INC.

/s/ MICHAEL LEVITZ

3 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Unregistered Sales of Equity Securities